Stockscreener 앱 받기
52.47
0.04%
0.02
시간 외 거래:
52.50
0.03
+0.06%
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
Real time social sentiment graph for BioMarin Pharmaceutical Inc.2025 Volume Leaders & Technical Analysis for Trade Confirmation - newser.com
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsEarnings Risk Report & Detailed Earnings Play Alerts - newser.com
Using flow based indicators on BioMarin Pharmaceutical Inc.July 2025 Institutional & Verified Short-Term Plans - newser.com
BioMarin stock price target lowered to $80 at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
BioMarin stock price target lowered to $80 at Cantor Fitzgerald - Investing.com
What data driven models say about BioMarin Pharmaceutical Inc.’s futureMarket Trend Review & Accurate Trade Setup Notifications - newser.com
Price momentum metrics for BioMarin Pharmaceutical Inc. explainedJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
BioMarin Pharmaceutical Inc. stock outlook for YEAR2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
What MACD signals say about BioMarin Pharmaceutical Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
Understanding BioMarin Pharmaceutical Inc.’s price movementQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Eyeing an 82% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat
Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat
Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com Nigeria
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - Yahoo Finance
MarketsFinancial Advisors - FinancialContent
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India
Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat
BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? - MSN
Biomarin Pharmaceutical expects Q3 will include acquired IPR&D charges of about $221 million - MarketScreener
BioMarin projects $221 million IPR&D charge from Inozyme acquisition - Investing.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
14 Biotech Stocks with High Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - sharewise.com
Real time alert setup for BioMarin Pharmaceutical Inc. performanceIPO Watch & Reliable Intraday Trade Plans - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Should Positive Phase 3 PALYNZIQ Results Prompt Action From BioMarin (BMRN) Investors? - Sahm
Robeco Institutional Asset Management B.V. Increases Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - MSN
Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story? - Yahoo Finance
5.15%
1.45%
자본화:
|
볼륨(24시간):